<DOC>
	<DOCNO>NCT02768402</DOCNO>
	<brief_summary>The purpose study assess safety performance Caisson Interventional Transcatheter MitralValve Replacement ( TMVR ) system treatment severe symptomatic MitralValve Regurgitation ( MR ) .</brief_summary>
	<brief_title>Caisson Transcatheter Mitral Valve Replacement ( TMVR ) System Early Feasibility Study</brief_title>
	<detailed_description>The treatment guideline valvular heart disease indicate surgical correction primary mitral valve regurgitation ( MR ) Class I recommendation . Further , recent evidence indicate valve replacement least effective repair primary secondary MR patient . However , many patient refer surgery consider high risk undergo pump , open-heart procedure . Percutaneous aortic valve replacement make treatment stenosed aortic valve available high-risk surgical patient would otherwise medically manage . Percutaneous mitral valve ( MV ) replacement offer similar advantage . Currently , approve percutaneous treatment MR MitraClip . MitraClip limit specific population high risk surgical patient valvular prolapse amenable repair edge edge technique . The feasibility percutaneous MV replacement show animal study , implantation aortic valve mitral position , early evaluation purpose make transcatheter MVs human . To meet medical need , Caisson Interventional develop percutaneous delivery system bioprosthetic mitral valve . As patient aortic valve ( AV ) deficiency , device use provide need therapy patient might otherwise receive treatment beyond medical therapy . This study provide initial information safety performance system .</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Has severe mitral regurgitation New York Heart Association ( NYHA ) Class II , III , IVa heart failure High risk cardiovascular surgery Excessive calcification thicken mitral valve annulus , severe mitral stenosis , fuse commissure , valvular vegetation mass Left ventricular end diastolic dimension &gt; 7cm Left ventricular outflow tract obstruction Severe right ventricular dysfunction Stroke within 90 day ; transischemic attack myocardial infarction within 30 day index procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Mitral Valve Regurgitation</keyword>
	<keyword>Primary MR</keyword>
	<keyword>Secondary MR</keyword>
	<keyword>MR</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Structural Heart</keyword>
	<keyword>Secondary Mitral Valve Regurgitation</keyword>
	<keyword>Primary Mitral Valve Regurgitation</keyword>
</DOC>